Zymeworks nets $61.5 mln in Series A round led by BDC, Lumira
Vancouver-based Zymeworks, a biotherapeutics company, has raised US$61.5 million in Series A mezzanine financing. BDC Capital and Lumira Capital led the round with participation from other investors that included Eli Lilly and Co, Celgene, CTI Life Sciences Fund, the Fonds de solidarité FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus. With the round, Dion Madsen, a senior managing partner at BDC Capital, will join Zymeworks’ board of directors, while Dr. Daniel Hétu, a managing director at Lumira Capital, will become an observer. The round's proceeds will support clinical development of Zymeworks' lead therapeutic candidates.
8 January 2016•4 mins read
